BMS-986256
Phase 1Small molecule
Bristol-Myers SquibbBMS-986256 is one of 29 small molecule programs targeting Cutaneous Lupus Erythematosus. It is currently in Phase 1.
1
Indications
8
Total Trials
0
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
32 competitors in Cutaneous Lupus Erythematosus
#DrugCompanyPhaseTrials
1Xeljanz
PPrism Pharmaceuticals
Approved
BMS-986165
Bristol-Myers SquibbApproved
Plaquenil
Alnylam PharmaceuticalsPhase 3
Trexall
Alnylam PharmaceuticalsPhase 3
Saphnelo
AstraZenecaPhase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Jyseleca
GileadPhase 2
Litifilimab
BiogenPhase 3
Prograf
VVeloxis Pharmaceuticals
Phase 2
Sotyktu
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Drug2 trials
Experimental1 trial
ART1 trial
Cutaneous Lupus Erythematosus1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BMS-986256. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company